Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19

Mazzitelli et al., Travel Medicine and Infectious Disease, 37, doi:10.1016/j.tmaid.2020.101826
Jul 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Report on HCQ+AZ use in 41 elderly high-risk patients. 29 of 30 patients with treatment >= 5 days survived. Only 10% were PCR negative after one week, however the Ct value is not specified.
Mazzitelli et al., 31 Jul 2020, peer-reviewed, 8 authors.
This PaperHCQAll
Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19
Maria Mazzitelli, Chiara Davoli, Vincenzo Scaglione, Paolo Fusco, Valentina La Gamba, Giovanni Matera, Enrico Maria Trecarichi, Carlo Torti
Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101826
Gautret at al. published results of non-randomized studies suggesting efficacy of hydroxychloroquine and azithromycin (HCQ/AZI) in patients with COVID-19 [1,2]. Particularly, among 80 mildly infected patients, 83% at day 7 and 93% at day 8 achieved negative results of RT-PCR for SARS-CoV-2 from nasopharyngeal swabs [2]. More recently, data from a multicenter study of 1061 patients were published, showing that all but one patient were PCR-cleared at day 15 [3]. Following the extraordinary success rate of the first study [1], we started prescribing HCQ/AZI in our patients, so from March 28th to April 4th, 2020, 41 patients took HCQ (200 mg thrice daily) and AZI 500 mg for the first day and 250 mg for the subsequent 4 days. All patients got infected from a unique outbreak in a long-term facility, with the date of infection estimated around a week before admission. So, in this study on an incident cohort, we minimized the risk of interpreting a rapid PCR clearance as an effect of the prescribed treatment, while such clearance may be simply spontaneous in patients infected for a longer time. Among 41 patients, ten died for severe COVID-19 (6 patients took treatment for ≤2 days, and 4 for <5 days), and one refused to be retested for SARS-CoV-2. So, 30 patients were evaluated after completion of the treatment course. Among them, 17 (51%) were females; median age was 83 years (IQR: 65-88). Recorded comorbidities were: hypertension (76.6%), neurological diseases (43.3%), chronic kidney disease (43.3%), and psychiatric disorders (33.3%). Nine (30%) patients were diagnosed with COVID-19 pneumonia (three requiring oxygen support). Twelve patients had upper respiratory symptoms. Five patients had respiratory failure without radiological evidence of pneumonia. Four patients were asymptomatic. Real time reverse transcriptase-polymerase chain reac-
Ethics approval and consent to participate Ethical approval of the protocol was obtained and consent for participation was obtained from each patients. Disclaimer The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Authors' contributions All authors conceived the study, carried out the analysis, discussed the results, drafted the first manuscript, revised the manuscript, and gave final approval for publication. Declaration of competing interest The authors declared no competing interests.
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Trav Med Infect Dis, doi:10.1016/j.tmaid.2020.101663
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Mazzitelli A, Davoli A, Scaglione A, Fusco A, La Gamba A et al., Carlo Torti a a Infectious and Tropical Disease Unit
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in marseille, France, Trav Med Infect Dis, doi:10.1016/j.tmaid.2020.101738
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop